Universal Beteiligungs und Servicegesellschaft mbH Buys 159,200 Shares of Puma Biotechnology, Inc. $PBYI

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 405.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 198,508 shares of the biopharmaceutical company’s stock after purchasing an additional 159,200 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Puma Biotechnology were worth $1,054,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PBYI. Ritholtz Wealth Management boosted its holdings in shares of Puma Biotechnology by 139.0% during the 3rd quarter. Ritholtz Wealth Management now owns 470,767 shares of the biopharmaceutical company’s stock worth $2,500,000 after buying an additional 273,782 shares during the period. Kathmere Capital Management LLC lifted its position in Puma Biotechnology by 38.4% during the third quarter. Kathmere Capital Management LLC now owns 27,953 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 7,749 shares during the last quarter. Baron Wealth Management LLC bought a new stake in shares of Puma Biotechnology during the third quarter worth approximately $116,000. Assenagon Asset Management S.A. acquired a new position in shares of Puma Biotechnology in the third quarter valued at approximately $388,000. Finally, Evergreen Capital Management LLC bought a new position in shares of Puma Biotechnology during the second quarter worth approximately $329,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on PBYI shares. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Puma Biotechnology in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Puma Biotechnology Trading Up 0.8%

NASDAQ PBYI opened at $6.48 on Friday. The company has a market cap of $326.53 million, a price-to-earnings ratio of 8.76 and a beta of 1.19. The company has a 50 day moving average of $5.88 and a 200-day moving average of $5.11. Puma Biotechnology, Inc. has a 1-year low of $2.58 and a 1-year high of $7.21.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12. The firm had revenue of $54.48 million for the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology had a return on equity of 36.17% and a net margin of 17.45%. On average, equities research analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Alan H. Auerbach sold 18,012 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $5.88, for a total value of $105,910.56. Following the completion of the transaction, the chief executive officer owned 7,145,951 shares of the company’s stock, valued at $42,018,191.88. The trade was a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Patrick Miller sold 20,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $4.86, for a total transaction of $97,200.00. Following the sale, the director directly owned 54,000 shares of the company’s stock, valued at $262,440. This represents a 27.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 63,937 shares of company stock worth $354,713. Company insiders own 23.30% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.